CYTEA BIO Competitors

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.

Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases.

Synthego is a CRISPR solutions provider that enables the acceleration of life science research and development in the pursuit of improved human health. Synthego is a pioneering force in the biotechnology industry, dedicated to advancing the frontiers of CRISPR cell and gene therapies through cutting-edge CRISPR technology and expertise. Our mission is to provide unparalleled access to best-in-class CRISPR solutions at scale, empowering agility in life science research and development from discovery through clinical trials. From streamlined approaches to licensing through full technical and regulatory support from our industry-leading experts, Synthego is enabling greater access to CRISPR technology driving to improved outcomes in patient therapeutic treatments. At Synthego, our values define who we are and how we work together to shape the future of science. Ingenuity drives us to innovate and solve complex challenges in groundbreaking ways. Collaboration fuels our success, as we believe the best ideas come from diverse perspectives working together. Kindness shapes our workplace culture, fostering mutual respect and care for one another. Empowerment inspires every team member to take initiative, grow, and make meaningful contributions. Integrity forms the foundation of everything we do, ensuring trust, transparency, and excellence guide our actions. We believe that fostering an environment of belonging is essential to driving innovation and collaboration. Through our Diversity Network Association (DNA), we actively amplify diverse voices, champion equity, and create spaces where inclusivity thrives. These principles are not just policies or initiatives; they’re integrated into our DNA and guide how we work together every day. By weaving diversity, equity, and inclusion into the fabric of our identity, we strengthen our team, inspire new ideas, and ensure everyone can contribute meaningfully to shaping the future of science.